Corcept is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Current information about Corcept’s clinical trials is available at ClinicalTrials.gov, including objectives, enrollment criteria, eligibility, and site locations.
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer
Some studies have suggested that certain signaling pathways help estrogen receptor negative breast cancer cells resist the effects of chemotherapy. Cortisol, a glucocorticoid stress hormone, plays an important role in activating pathways in these cells that allow them to survive despite chemotherapy. By targeting the glucocorticoid receptor (GR) with mifepristone, this downstream cell survival response may be prevented, allowing chemotherapy to be more effective against metastatic or locally advanced breast cancer.
The phase 1 trial “Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer” is to assess the safety and preliminary efficacy of the combination of mifepristone and eribulin (a chemotherapy agent) in patients with metastatic or locally-advanced unresectable, GR positive Triple Negative Breast Cancer (TNBC).
To learn more about this trial, including its objectives, enrollment criteria, eligibility, and site locations, visit ClinicalTrials.gov.